API-192 is a first-in-class off-the-shelf allogeneic CAR-NKT cell therapy that expresses dual CARs targeting CD19 and CD20 and armored with soluble IL-15 for improved expansion and persistence API-192 is the first development candidate out of 2021 collaboration and license agreement with…